Utidelone

A chemotherapeutic agent derived from a natural product

Utidelone
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Utidelone is a chemotherapeutic agent that is derived from a natural product. It is a semi-synthetic analog of epothilone, a class of microtubule-stabilizing agents that have shown promise in the treatment of various cancers. Utidelone is particularly noted for its potential use in treating breast cancer and other solid tumors.

Chemical Structure and Properties

Utidelone is a complex macrolide compound that is structurally related to other epothilones. The chemical structure of utidelone allows it to bind to tubulin, a protein that is essential for microtubule formation. By stabilizing microtubules, utidelone disrupts the normal process of cell division, leading to apoptosis or programmed cell death in rapidly dividing cancer cells.

Chemical structure of Utidelone

Mechanism of Action

Utidelone exerts its effects by binding to the β-tubulin subunit of microtubules. This binding prevents the depolymerization of microtubules, which is a critical step in the mitotic spindle formation during mitosis. As a result, utidelone effectively halts the cell cycle in the G2/M phase, leading to cell death. This mechanism is similar to that of other microtubule-stabilizing agents such as paclitaxel and docetaxel, but utidelone may offer advantages in terms of reduced drug resistance and improved pharmacokinetics.

Clinical Applications

Utidelone has been investigated in clinical trials for its efficacy in treating various types of cancer. It has shown promise in the treatment of metastatic breast cancer, particularly in patients who have developed resistance to other chemotherapeutic agents. The drug is often administered in combination with other agents, such as capecitabine, to enhance its therapeutic effects.

Side Effects

Like many chemotherapeutic agents, utidelone is associated with a range of side effects. Common adverse effects include neutropenia, peripheral neuropathy, nausea, and fatigue. The severity of these side effects can vary depending on the dosage and the individual patient's response to the treatment.

Research and Development

Research into utidelone continues, with ongoing studies aimed at optimizing its use in cancer therapy. Scientists are exploring various combinations of utidelone with other chemotherapeutic agents to improve its efficacy and reduce side effects. Additionally, research is focused on understanding the molecular mechanisms underlying its action to develop more targeted cancer therapies.

Related Pages

• Epothilone
• Microtubule-stabilizing agent
• Breast cancer
• Chemotherapy